Novartis Raises Full-Year Guidance Following Strong Q1 Performance

The Swiss pharmaceutical giant outperforms expectations with significant sales increases in key drugs, prompting an upward revision in financial forecasts.

• Novartis reports a robust first-quarter with sales rising 9.5% to $11.83 billion, driven by strong demand for blockbuster drugs Entresto and Cosentyx.
• CEO Vas Narasimhan highlights broad-based growth across all major brands and regions, with Entresto sales jumping 36% and Cosentyx sales up 25%.
• Full-year sales are now expected to grow by a high-single to low-double-digit percentage, while core operating income is projected to increase by a low-double-digit to mid-teens percentage.
• Shares of Novartis climbed as much as 4.8% in early trading following the positive financial update.
• The company continues to advance its drug pipeline, including new treatments for prostate cancer and leukemia, and plans to propose a new chair for its board in 2025.

3 Articles

Investopedia CNBC CNBC